Clinical Trial Update: Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of CD5789 (trifarotene) 50 µg/g cream versus vehicle in acne vulgaris has completed with posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• CD5789 (Trifarotene) 50µg/g Cream (trifarotene)

Snippet

Sponsor: Galderma R&D | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2019-09-03